Saturday 17 October 2026
Export BLRX’s income statement to Excel — free account
BioLineRx Ltd.
BLRX Healthcare Biotechnology
BioLineRx Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 million, down 95.9% from fiscal 2024. In the quarter to June 2026, revenue fell 3.29%, EPS grew 23.0%, free cash flow fell 1,827.7% and total debt fell 40.2%, each against the same quarter a year earlier.
2.04
0.01
−0.49%
Follow BLRX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
9.95 | 7.27 | 9.65 | 1.29 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(4.31) | (4.47) | (3.56) | (7.80) | |
P/B ratio |
0.83 | 0.49 | 0.49 | 0.84 | |
Price to Tangible BV |
47.62 | 2.27 | 1.63 | 1.80 | |
EV/Sales |
5.37 | 0.49 | (0.47) | 0.10 | |
EV/EBITDA |
0.00 | 0.00 | 0.06 | 0.00 | |
EV/Operating CF |
(0.69) | (0.09) | 0.07 | (0.10) | |
EV/FCF |
(0.69) | (0.09) | 0.07 | (0.09) | |
Quick Ratio |
1.01 | 1.41 | 1.76 | 1.90 | |
Current Ratio |
1.20 | 1.58 | 1.95 | 2.09 | |
Net Debt/EBITDA |
1.83 | 3.26 | 3.59 | 7.25 | |
Debt/Assets |
20.01% | 20.20% | 21.85% | 25.32% | |
Debt/Equity |
0.40 | 0.38 | 0.38 | 0.52 | |
Asset Turnover |
0.04 | 0.03 | 0.03 | 0.28 | |
Operating CF/Net income |
1.06 | 1.42 | 2.31 | 2.16 | |
Capex/Depreciation |
0.22 | (0.07) | (0.43) | 0.00 | |
Interest Coverage |
(17.18) | (12.02) | (12.09) | (7.26) | |
Research and Development Expense of Revenue |
1,001.02% | 529.98% | 1,250.00% | 402.58% | |
Selling, General and Administrative Expense of Revenue |
294.22% | 179.87% | 574.74% | 194.61% | |
Intangible Assets out of Total Assets |
0.49 | 0.42 | 0.40 | 0.26 | |
Share Based Compensation of Revenue |
26.87% | 16.35% | 24.74% | 23.65% | |
Graham Net Nets |
(0.04) | 0.36 | 0.54 | 0.50 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(54.17%) | (83.48%) | (6.14%) | (36.87%) | |
Free Cash Flow Yield |
(78.21%) | (76.56%) | (71.28%) | (82.68%) | |
Revenue per Share |
0.07 | 0.11 | 0.05 | 0.10 | |
Operating CF per Share |
(0.72) | (0.51) | (0.78) | (0.48) | |
Capex per Share |
0.00 | 0.00 | (0.01) | 0.00 | |
Free Cash Flow per Share |
(0.72) | (0.52) | (0.79) | (0.48) | |
Cash per Share |
2.94 | 3.91 | 5.08 | 5.80 | |
Shareholders Equity per Share |
3.74 | 4.70 | 5.68 | 4.50 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.74 | 4.70 | 5.68 | 4.50 | |
Free Cash Flow |
(3.20) | (2.29) | (3.23) | (2.11) | |
Working Capital |
2.67 | 7.96 | 11.56 | 14.86 | |
Capital Expenditures |
0.02 | (0.01) | (0.03) | — | |
Net Current Asset Value |
(0.51) | 3.62 | 6.12 | 8.25 | |
EV/EBIT |
0.00 | 0.00 | 0.05 | 0.00 | |
Capex to Sales |
(0.06) | 0.01 | 0.14 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.50 | 1.91 | 2.21 | 2.33 | |
Average Payables |
6.37 | 6.80 | 6.98 | 6.83 | |
Average Inventory |
2.51 | 2.74 | 2.65 | 2.86 | |
Average Assets |
38.37 | 41.15 | 39.91 | 46.27 | |
Average Common Equity |
18.35 | 20.85 | 18.40 | 14.02 |
Columns are period end dates